Hospital Pharmacy - April 2018 - 126

126

Hospital Pharmacy 53(2)

Table 1. Physical Compatibility Results of Micafungin With Three different Vehicles.

Vehicle
40SB-D5W-1/4NS
75SB-D5W
154SB-D5W

pH range over 2-h
observation period
(delta)

Change turbidity
(NTU)

Visual
appearance

Odor

Evolution
of gas

8.4-8.6 (0.2)
8.4-8.6 (0.2)
8.4-8.7 (0.3)

0.29-0.39 (0.10)
0.31-0.39 (0.08)
0.31-0.48 (0.17)

Clear/colorless
Clear/colorless
Clear/colorless

None
None
None

None
None
None

Result
Compatible
Compatible
Compatible

Note. Data represents changes or observations as compared with both vehicle comparator and Time 0 sample. 40SB-D5W-1/4NS: Sodium bicarbonate
(40 mEq/L) with 5% dextrose in 0.225% hypotonic saline. 75SB-D5W: Sodium bicarbonate (75 mEq/L) with 5% dextrose in water. 154SB-D5W: Sodium
bicarbonate (154 mEq/L) with 5% dextrose in water. Changes are over the 120-minute observation period relative to the initial reading (0 minute) time
point. NTU = nephelometric turbidity units.

chloride (NS) or a 5% dextrose in water (D5W) vehicle.
Currently, there is no physical compatibility data available
for micafungin dosing via a Y-site/CVC with sodium bicarbonate. The purpose of this study is to determine the physical
compatibility of sodium bicarbonate hydration fluids and
micafungin via intravenous Y-site/CVC administration.

Materials and Methods
All drugs and vehicles were obtained from hospital stock and
used prior to their expiration dates. Micafungin sodium
(Astellas Pharma, Northbrook, Illinois; lot number 024260,
Expiration date: 02/2019) was reconstituted with NS to produce a concentration of 10 mg/mL which was further diluted
in NS to a final dose concentration of 1.5 mg/mL. These
solutions were used immediately after preparation. The vehicle solutions (40SB-D5W-1/4NS, 75SB-D5W, and
154SB-D5W) were used as received from the hospital pharmacy. A stock 100 mL volume of each micafungin:vehicle
combination was made by adding 1 part of freshly prepared
micafungin to 3 parts of each vehicle. This stock was divided
into aliquots of appropriate size for evaluation of each
parameter. The 3 vehicles (40SB-D5W-1/4NS, 75SB-D5W,
and 154SB-D5W) without micafungin added were used as
comparators in this study.
Observations were conducted at room temperature under
standard laboratory LED lighting for micafungin in each
vehicle to determine physical compatibility at baseline (Time
0) and at 15, 30, 45, 60, 75, 90, 105, and 120 minutes after
mixing. Recorded observations at each time point were compared with both the vehicle comparators and the time 0 evaluation of the mixture. Physical incompatibility was defined
as visual detection of the formation of particles, crystals,
cloudiness, evolution of gas or a noted change in the odor, or
color.4 The visual observations conducted by 2 independent
observers of each formulation in borosilicate glass included
viewing the solution against matte black and nonglare white
backgrounds as well as in the absence of a specific background. Turbidity was measured using a laboratory-grade
turbidimeter (2100Q Turbidimeter, Hach, Loveland,
Colorado) calibrated on each day of use using StablCal calibration standards (0.5, 1, 10, 20, 100 nephelometric turbidity
units [NTU]) commercially available from Hach following

the manufactures instruction provided with the instrument.
All measurements were made in reusable glass sample cells
obtained from the manufacturer. A turbidity change of ≥0.5
NTU as compared with either the comparator or the time 0
baseline sample indicated physical incompatibility.5
Measurements of pH were made with pH meter (Ohaus
Starter 2100, Parsippany, New Jersey) calibrated at pH 4, 7,
and 10 using calibration buffer solutions on each day of use.
Each sample and comparator was continuously stirred in
borosilicate glass beakers during the measurement period. A
pH change of ≥1.0 was set a priori as compared with the time
0 or comparator solution as an indication of physical incompatibility based on several previously published studies.6-9

Results and Discussion
Micafungin, when reconstituted to 10 mg/mL with NS and
further diluted to 1.5 mg/mL with NS (final tested concentration) remained clear and colorless throughout the 2-hour
observation period. Prior to mixing, all vehicles and control
solutions were also clear and colorless throughout the observation period. Likewise, there were no significant changes in
turbidity, pH, or odor in any of the vehicle controls.
When micafungin (1.5 mg/mL in NS) was mixed individually with each of the 3 vehicles evaluated (40SB-D5W-1/4NS,
75B-D5W, 154SB-D5W), the resulting mixtures were observed
to be compatible (Table 1) throughout the 2-hour observation
period based on the predefined criteria. For each of the 3 mixtures, there were no observed changes in the visual assessments
regarding color or clarity as determined by 2 independent
observers. In addition, there was no evidence of crystal or precipitate formation as compared against the baseline or the vehicle comparators. Likewise, there was no detectable change in
odor of the mixtures as compared with the baseline or controls.
Changes in measured turbidity of the samples as compared
with the vehicle comparators were all less than 0.5 NTU for the
duration of the study. Actual measured turbidity values of the
samples were in the range of 0.29 to 0.48 NTU, while those for
the comparators were in the range of 0.13 to 0.26 NTU for each
time point over the 2-hour observation period. Specific ranges
for each mixture are shown in Table 1. The measured pH
values of the samples as compared with the vehicle comparators also supported the samples being compatible.



Table of Contents for the Digital Edition of Hospital Pharmacy - April 2018

Ed Board
TOC
HPX
Why Is Burnout a Taboo?
Stability of 2 mg/mL Adenosine Solution in Polyvinyl Chloride and Polyolefin Infusion Bags
Glecaprevir/Pibrentasvir
New Medications in the Treatement of Acute Decompensated Heart Failure
The Prescription Drug User Fee Act: Cause for Concern?
ISMP Medication Error Report Analysis
ISMP Adverse Drug Reactions
Development and Implementation of a Combined Master of Science and PGY1/PGY2 Health-System Pharmacy Administration Residency Program at a Large Community Teaching Hospital
Breadth of Statistical Training Among Pharmacy Residency Programs Across the United States
Antihypertensive Prescription Pattern and Compliance to JNC 7 and JNC 8 at Tertiary Care Government Hospital, Hyderabad, India: A Cross-sectional Retrospective Study
Changes in Pharmacy Residency Training Design Between 2012 and 2017: A Perspective of Academic Medical Centers
Incidence of Hypoglycemia in Burn Patients: A Focus for Process Improvement
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy
Hospital Pharmacy - April 2018 - Cover1
Hospital Pharmacy - April 2018 - Cover2
Hospital Pharmacy - April 2018 - Ed Board
Hospital Pharmacy - April 2018 - TOC
Hospital Pharmacy - April 2018 - HPX
Hospital Pharmacy - April 2018 - Why Is Burnout a Taboo?
Hospital Pharmacy - April 2018 - Stability of 2 mg/mL Adenosine Solution in Polyvinyl Chloride and Polyolefin Infusion Bags
Hospital Pharmacy - April 2018 - 74
Hospital Pharmacy - April 2018 - Glecaprevir/Pibrentasvir
Hospital Pharmacy - April 2018 - 76
Hospital Pharmacy - April 2018 - 77
Hospital Pharmacy - April 2018 - 78
Hospital Pharmacy - April 2018 - 79
Hospital Pharmacy - April 2018 - 80
Hospital Pharmacy - April 2018 - 81
Hospital Pharmacy - April 2018 - 82
Hospital Pharmacy - April 2018 - 83
Hospital Pharmacy - April 2018 - 84
Hospital Pharmacy - April 2018 - New Medications in the Treatement of Acute Decompensated Heart Failure
Hospital Pharmacy - April 2018 - 86
Hospital Pharmacy - April 2018 - 87
Hospital Pharmacy - April 2018 - The Prescription Drug User Fee Act: Cause for Concern?
Hospital Pharmacy - April 2018 - 89
Hospital Pharmacy - April 2018 - ISMP Medication Error Report Analysis
Hospital Pharmacy - April 2018 - 91
Hospital Pharmacy - April 2018 - 92
Hospital Pharmacy - April 2018 - ISMP Adverse Drug Reactions
Hospital Pharmacy - April 2018 - 94
Hospital Pharmacy - April 2018 - 95
Hospital Pharmacy - April 2018 - Development and Implementation of a Combined Master of Science and PGY1/PGY2 Health-System Pharmacy Administration Residency Program at a Large Community Teaching Hospital
Hospital Pharmacy - April 2018 - 97
Hospital Pharmacy - April 2018 - 98
Hospital Pharmacy - April 2018 - 99
Hospital Pharmacy - April 2018 - 100
Hospital Pharmacy - April 2018 - Breadth of Statistical Training Among Pharmacy Residency Programs Across the United States
Hospital Pharmacy - April 2018 - 102
Hospital Pharmacy - April 2018 - 103
Hospital Pharmacy - April 2018 - 104
Hospital Pharmacy - April 2018 - 105
Hospital Pharmacy - April 2018 - 106
Hospital Pharmacy - April 2018 - Antihypertensive Prescription Pattern and Compliance to JNC 7 and JNC 8 at Tertiary Care Government Hospital, Hyderabad, India: A Cross-sectional Retrospective Study
Hospital Pharmacy - April 2018 - 108
Hospital Pharmacy - April 2018 - 109
Hospital Pharmacy - April 2018 - 110
Hospital Pharmacy - April 2018 - 111
Hospital Pharmacy - April 2018 - 112
Hospital Pharmacy - April 2018 - Changes in Pharmacy Residency Training Design Between 2012 and 2017: A Perspective of Academic Medical Centers
Hospital Pharmacy - April 2018 - 114
Hospital Pharmacy - April 2018 - 115
Hospital Pharmacy - April 2018 - 116
Hospital Pharmacy - April 2018 - 117
Hospital Pharmacy - April 2018 - 118
Hospital Pharmacy - April 2018 - 119
Hospital Pharmacy - April 2018 - 120
Hospital Pharmacy - April 2018 - Incidence of Hypoglycemia in Burn Patients: A Focus for Process Improvement
Hospital Pharmacy - April 2018 - 122
Hospital Pharmacy - April 2018 - 123
Hospital Pharmacy - April 2018 - 124
Hospital Pharmacy - April 2018 - Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy
Hospital Pharmacy - April 2018 - 126
Hospital Pharmacy - April 2018 - 127
Hospital Pharmacy - April 2018 - 128
Hospital Pharmacy - April 2018 - Cover3
Hospital Pharmacy - April 2018 - Cover4
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com